The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
A game changing solution for the pharmaceutical industry
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated